Skip to main content
Brigatinib may prevent brain metastases in NSCLC, study shows

Treatment with brigatinib, or Alunbrig, showed substantial response in patients with non-small cell lung cancer and intracranial involvement, according to a study published in the Journal of Clinical Oncology. Researchers feel that brigatinib holds promise as a potential first-line treatment to delay or prevent brain metastases.

Full Story: